Andrew Czysz

1 presentation

T89. ML-007C-MA, A NOVEL INVESTIGATIONAL M1/M4 MUSCARINIC AGONIST IN PHASE 2 DEVELOPMENT FOR THE TREATMENT OF SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS

2026 ASCP Annual Meeting